Shattuck Labs, Inc.

STTK

$6.79

-2.44%

2026-09-04 11:10:58 EDT-$0.17

Healthcare

Biotechnology

NASDAQ

Active Trading

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission ...

Price Action of STTK

$6.79

-2.44%-$0.17

High—

Low—

52W High-18.5%

Rel. vol—

Interval

Range1.7h

Volume—SMA5SMA10

—

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for cancer and autoimmune diseases. The company was founded in 2016 and is headquartered in Austin, Texas, with R&D facilities in Durham, North Carolina. It was originally focused on dual agonists, but has pivoted to DR3-targeting antibodies. ...Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for cancer and autoimmune diseases. The company was founded in 2016 and is headquartered in Austin, Texas, with R&D facilities in Durham, North Carolina. It was originally focused on dual agonists, but has pivoted to DR3-targeting antibodies. Its lead product candidate, SL-172154, is an antibody fusion protein designed to block CD47 and activate CD40, and has entered Phase 1 trials for ovarian, fallopian tube, and peritoneal cancers. Another candidate, SL-279252, is a PD-1-targeting agonist for solid tumors and lymphoma. However, the company has recently shifted its pipeline towards inflammatory bowel disease (IBD) and other immune-mediated diseases, with a focus on a first-in-class antibody targeting DR3. As of the latest data, the company has 40 full-time employees according to FMP, but annual reports show 105 employees in 2022, indicating a small organization. Financially, the company is in a development stage with no revenue, and its financial metrics reflect heavy R&D and SG&A spending, with net losses and negative cash flow. The market cap is around $347 million, and the stock trades on NASDAQ. The company went public in October 2020 with an IPO that raised approximately $202 million. Key personnel include CEO Taylor H. Schreiber, who is a co-founder and previously served as CSO. The company's focus on DR3-targeting antibodies for IBD represents a strategic shift from its earlier oncology focus, and it aims to raise the standard of care in chronic immune-related diseases. With a strong cash position (quick ratio of 22) and no debt, the company is well-capitalized to advance its pipeline, but will need to manage its cash burn as it progresses through clinical trials.ExpandCollapse

Founded

2016

Employees

CEO

Taylor H. Schreiber

Full Name

Shattuck Labs, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-43.57%

Market Cap

$0.68B

Current Ratio

27.59

WACC

9.73%

ROIC

-25.03%

Contact Information

https://www.shattucklabs.com

512 900 4690

500 West 5th Street, Austin, TX 78701

Key Metrics of STTK

Snapshot

Latest / TTM · 6 periods

Market Cap

$681.47M

ROCE

-26.2%

EV / EBITDA

-11.43x

+35.1% YoY

FCF Yield

-6.7%

+9.0% YoY

Cash Conversion Cycle

-169.1d

Current Ratio

27.59

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of STTK

Profitability trend

Latest / TTM · 6 periods

Gross Margin

-750.9%

Net Margin

-5256.8%

P/E Ratio

-13.65x

n/a

Debt / Equity

0.01

n/a

Current Ratio

27.59

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of STTK

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.11 · Revenue $37500.00 · 7 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.11 · Revenue $100000.00 · 8 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.48 · Revenue $105000.00 · 8 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.11 · Revenue $75000.00 · 3 analysts

Recent history

Aug 11, 2026
Q2 FY2026 · Results reported
EPS $-0.12 · Revenue $0.00
View filing
May 7, 2026
Q1 FY2026 · Results reported
EPS $-0.13 · Revenue $0.00
View filing
Mar 5, 2026
FY2025 · Annual results
EPS $-0.70 · Revenue $1.00M
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-0.14 · Revenue $1.00M
View filing
Aug 14, 2025
Q2 FY2025 · Results reported
EPS $-0.24 · Revenue $0.00
View filing
May 1, 2025
Q1 FY2025 · Results reported
EPS $-0.27 · Revenue $0.00
View filing

Financial Statements of STTK

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$1.0M	-82.5%	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-48.8M	+35.3%	-2.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	-195.1%	-1449.7%	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-5150.8%	-265.8%	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-4880.9%	-270.3%	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-40.0M	+34.0%	+23.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-3995.3%	-277.3%	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	2.9%	-31.3%	-58.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	11.70x	+31.7%	+25.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$91.0M	-0.0%	+116.1%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.70 vs -0.77	+8.8%	-0.12 vs -0.12	+3.3%
Revenue Surprise	$1.0M vs $1.2M	-14.3%	—	—

Insider Transactions of STTK

Acquisitions (A)

Since Jun 30, 2026

Disposals (D)

Since Jun 30, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 6, 2026	Shukla Abhinav A.	officer: Chief Technical Officer	Common Stock	A	12,153	$3.57
Jul 6, 2026	Shukla Abhinav A.	officer: Chief Technical Officer	Stock Option (Right to Buy)	D	12,153	$3.57
Jul 2, 2026	Shukla Abhinav A.	officer: Chief Technical Officer	Common Stock	A	410	$3.57
Jul 2, 2026	Shukla Abhinav A.	officer: Chief Technical Officer	Common Stock	D	410	$7.01
Jul 2, 2026	Shukla Abhinav A.	officer: Chief Technical Officer	Stock Option (Right to Buy)	D	410	$3.57

Leadership Team of STTK

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Taylor H. Schreiber	Co-Founder, Chief Executive Officer & Director	USD 876,232	—	1980	Active
Arundathy Nirmalini Pandite	Chief Medical Officer	USD 734,899	—	1959	Active
Andrew R. Neill	Chief Financial Officer	USD 678,207	Male	1986	Active
Abhinav A. Shukla	Chief Technical Officer	USD 567,398	—	1973	Active
Casi DeYoung	Chief Business Officer	USD 523,482	Female	1971	Active
Suresh de Silva	Chief Scientific Officer	—	Male	—	Active
Brad Huckabee	Vice President of Accounting & SEC reporting	—	Male	—	Active
Kelli Collin	Senior Vice President of Quality	—	Female	—	Active
Thomas Lampkin	Senior Vice President of Regulatory Affairs	—	—	—	Active
Stephen Stout	General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer	—	Male	1975	Active

Recent News of STTK

The Motley Fool8/24/2026Neutral

What Shattuck Labs Stock Topped the Market on Monday

One of them initiated coverage. The company has a very promising lead drug candidate.

Zacks Investment Research8/20/2026Neutral

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Defense World8/14/2026Neutral

Geron (NASDAQ:GERN) and Shattuck Labs (NASDAQ:STTK) Head to Head Comparison

Geron (NASDAQ: GERN - Get Free Report) and Shattuck Labs (NASDAQ: STTK - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership. Valuation and Earnings This table compares Geron and

Zacks Investment Research8/13/2026Neutral

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

The consensus price target hints at an 85.3% upside potential for Shattuck Labs (STTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The Motley Fool7/24/2026Neutral

Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

He was encouraged by the progress of the company's SL-325. This, the biotech's lead drug candidate, is about to enter Phase 2 clinical testing.

Historical Employee Count of STTK

Current

Change

-9.09%

Minimum

Maximum

105

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	40	10-K	Mar 5, 2026	View
Dec 31, 2024	44	10-K	Mar 27, 2025	View
Dec 31, 2023	75	10-K	Feb 29, 2024	View
Dec 31, 2022	105	10-K	Feb 23, 2023	View
Dec 31, 2021	85	10-K	Mar 15, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Shattuck Labs, Inc.